A Phase 3 interventional study of glepaglutide in Short Bowel Syndrome, sponsored by Zealand Pharma. Completed at 27 sites in 9 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Zealand Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Short Bowel Syndrome with a site in United States — 11 open to participants now, 15 under way, 4 of them phase 3. Short Bowel Syndrome · United States.
Among the 80 studies in Short Bowel Syndrome with a site in United States, this one is the 4th largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2019, is one of 20 in phase 3, and was the 56th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →11 of the 80 studies in Short Bowel Syndrome with a site in United States are open now. Recruiting first, the newest first:
VectivBio AG · Sites in United States, Argentina, Australia and 19 more countries
Ages 18+
Zealand Pharma · Sites in United States, Austria, Belgium and 11 more countries
Ages 18–90
Eclipse Regenesis, Inc. · Sites in United States
Ages 3 mo–65 yrs
Children's Hospital of Philadelphia · Sites in United States
Ages 4 mo–18 yrs · Healthy volunteers
Hanmi Pharmaceutical Company Limited · Sites in United States, Belgium, Denmark and 5 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 23 · Phase 4 7
First in 1996; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 23 across the 66 interventional studies, 143 across the 10 observational. Of the 52 that completed or were terminated, 29 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 80 have an industry lead sponsor. The 10 most frequent:
Zealand Pharma is the lead sponsor of 43 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
Zealand Pharma has 7 studies filed under Short Bowel Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Short Bowel Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05018286Phase 3VectivBio AGOpen-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. | 2027-10-30 |
| NCT06240065University of Texas Southwestern Medical CenterSuccessful Fiber Food Introduction in Short Bowel Syndrome | 2027-04 |
| NCT03530852Boston Children's HospitalA 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB | 2027-06-30 |
| NCT05432648Children's Hospital of PhiladelphiaFiber Food Introduction in Pediatric Short Bowel Syndrome | 2027-08-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 80 studies in Short Bowel Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS).
Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients with Short Bowel Syndrome (SBS)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection twice weekly. In this long term safety study, there is no placebo arm.
Drug: glepaglutide
Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection once weekly and placebo once weekly. In this long term safety study, there is no placebo arm.
Drug: glepaglutide
Glucagon-Like Peptide-2 (GLP-2) analog
Also known as: ZP1848
Safety - Adverse Events
Incidence and type of Adverse Events
Time frame: 2 years
Safety - Serious Adverse Events
Incidence and type of Serious Adverse Events
Time frame: 2 years
Safety - Adverse Events of Special Interest
Incidence and type of Adverse Events of Special Interest
Time frame: 2 years
Safety - Changes in blood pressure from baseline
Changes in systolic and diastolic blood pressure will be reported
Time frame: 2 years
Number of patients with clinically significant changes in 12-Lead electrocardiogram (ECG)
Number of patients with clinically significant changes in ECG will be reported
Time frame: 2 years
Immunogenicity - Occurrence of anti-drug antibodies
Occurrence of antibodies against glepaglutide
Time frame: 2 years
Change in weekly Parenteral Support (PS) volume
Change in weekly PS volume from baseline
Time frame: 2 years
Number of patients with 20 percent reduction in PS volume
Achieving at least 20 percent reduction in weekly PS volume from baseline
Time frame: 2 years
Days off PS
Achieving 1 or more days per week off PS
Time frame: 2 years
Weaned off PS
Reduction in weekly PS volume of 100 percent (weaned off)
Time frame: 2 years
Changes in fluid composite effect
Reduction in PS plus reduction in oral fluid intake plus increase in urine volume from baseline
Time frame: 2 years
Energy content (lipids)
Change in lipids content (in kcal/L or kjoule/L) of PS from baseline
Time frame: 2 years
Energy content (glucose)
Change in glucose content (in kcal/L or kjoule/L) of PS from baseline
Time frame: 2 years
Energy content (amino acids)
Change in amino acids content (in kcal/L or kjoule/L) of PS from baseline
Time frame: 2 years
Days on PS
Change in number of days on PS per week from baseline
Time frame: 2 years
Number of patients with 40 percent change in PS volume per week
Achieving 40 percent in PS volume from baseline
Time frame: 2 years
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from May 2019 to primary completion in Apr 2026, 83 months.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 83 months is above that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glepaglutide